Hogan Lovells represents LabCorp in an offering of over US$1billion in senior notes and a concurrent US$300 million cash tender offer
New York, 20 November 2019 – Global law firm Hogan Lovells is representing LabCorp, a leading global life sciences company, in an offering of over US$1 billion principal amount of senior notes and a concurrent cash tender offer for up to US$300 million principal amount of outstanding notes.
The offering consists of two tranches: US$400 million aggregate principal amount of 2.300% Senior Notes due 2024 and US$650 million aggregate principal amount of 2.950% Senior Notes due 2029. The closing of the offering is expected to occur on 25 Nov. 2019, subject to the satisfaction of customary closing conditions.
Concurrently with this offering, LabCorp is conducting a cash tender offer for up to US$300 million aggregate purchase price of its 4.625% Senior Notes due 15 Nov. 2020.
The Hogan Lovells team that advised LabCorp was led by partners Michael Silver, William Intner and Stuart Morrissy, counsel Jessica Bisignano, and associates Philip Schuster, Laura Heller and Yiyang Cheng.
Hogan Lovells has advised LabCorp for more than a decade on many of its most significant securities offerings and strategic acquisitions including acquisitions of: Envigo’s nonclinical contract research services business, Chiltern, Covance, Genzyme Genetics, Pathology Associates Medical Laboratories (PAML), Mount Sinai Health System Clinical Outreach Laboratories, Monogram Biosciences, Medtox, Liposcience and Sequenom.